BDPT BioAdaptives Inc

Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial

Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial

LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results with minimal side effects, marking a crucial product development milestone.

During the trial, participants experienced weight loss ranging from 5 to 7 pounds per week. Side effects were minimal, with the most common being mild gastrointestinal discomfort, which was easily managed by increasing water intake or adjusting the product dosage.

"We are thrilled with the results of this dosage trial," said James Keener, CEO. "The consistent weight loss across participants, coupled with the manageable side effect profile, indicates that Zeranovia™ has the potential to be a game-changer in the weight loss market."

Key findings from the dosage trial include:

  • Consistent weight loss across participants
  • Minimal side effects, easily managed with simple adjustments
  • High participant satisfaction, with all trial subjects requesting to proceed to the next phase

Based on these promising results, BioAdaptives is moving forward with dosage adjustments for the next stage of clinical trials. The company is optimistic about the product's potential to address the growing global need for effective and safe weight loss solutions.

"The enthusiasm from our trial participants is incredibly encouraging," added Keener. "Their eagerness to continue with the next phase of testing speaks volumes about the product's effectiveness and tolerability."

BioAdaptives is committed to developing innovative solutions for weight management. The company anticipates releasing further updates as the clinical trial progresses.

About BioAdaptives, Inc.

BioAdaptives, Inc. (OTC: BDPT) is a leading innovator in the health and wellness industry. We are dedicated to developing and marketing nutraceutical and wellness products that harness the power of natural ingredients and cutting-edge science. Our mission is to improve the quality of life for our customers by offering products that support optimal health and vitality.

For more information, please visit our website at .

Contact Information:

BioAdaptives, Inc.

Emily Harrison

IR Coordinator

(702)-659-8829



2620 Regatta Dr, Suite 102

Las Vegas, NV 89128

Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, statements regarding expected growth, potential benefits of the company's products, and future business opportunities. These statements involve risks, uncertainties, and other factors that may cause actual results or developments to differ materially from those expressed or implied.

Wire Service Contact:

IBN

Austin, Texas



512.354.7000 Office



EN
13/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioAdaptives Inc

 PRESS RELEASE

BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge ...

BioAdaptives Announces National Launch of NeuroRush™ — A Cutting-Edge Adaptogenic Nootropic for Mental Clarity, Focus, and Resilience NeuroRush™ delivers a unique blend of adaptogens and nootropic herbs designed to enhance cognitive performance, stress response and long-term brain health, without dependency or burnout. LAS VEGAS, July 16, 2025 (GLOBE NEWSWIRE) -- (OTC: BDPT), an innovator in evidence-based wellness solutions, today announced the upcoming national release of NeuroRush™, a next-generation nootropic designed to support sustained cognitive performance, mental clarity, and ...

 PRESS RELEASE

BioAdaptives Announces National Launch of Pawpa™ Regen

BioAdaptives Announces National Launch of Pawpa™ Regen Revolutionary Canine Supplement Promotes Regenerative Healing Through Stem Cell Activation LAS VEGAS , June 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- (OTC Pink: BDPT), an innovator in nutraceutical and wellness science, today announces the upcoming national release of , a proprietary canine supplement that supports natural stem cell activation and regenerative healing in aging dogs. After a successful limited market release earlier this year, Pawpa™ Regen officially launches nationwide at the end of July 2025. This breakthrough form...

 PRESS RELEASE

BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for...

BioAdaptives® PawPa™ Regen Provides Breakthrough Stem Cell Support for Pets, Backed by Clinically Proven APBAR® Scale Improvements Regen Dog Chews are crafted to the highest quality standards, recommended by veterinarians and proven safe with no adverse effects reported in clinical trials LAS VEGAS, May 28, 2025 (GLOBE NEWSWIRE) -- via IBN -- . (OTC: BDPT), through its pets division PawPa™, a leader in premium pet wellness, proudly announces the remarkable stem cell benefits of its flagship product, Regen Dog Chews, validated through rigorous clinical testing and the innovative APBAR® r...

 PRESS RELEASE

Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Tr...

Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results with minimal side effects, marking a crucial product development milestone. During the trial, participants experienced weight loss ranging from 5 to 7 pounds per week. Side effects were minimal, with the most common being mild gastrointestinal discomfort, which was e...

 PRESS RELEASE

BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of...

BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors Harris, the Senior Vice President of Athlete Development and Marketing at the Ultimate Fighting Championship, has a distinguished career spanning over 40 years LAS VEGAS, Feb. 06, 2025 (GLOBE NEWSWIRE) -- via IBN –  (OTC: BDPT), a leading biotechnology company focused on innovative health and wellness solutions, proudly announces the appointment of Reed Harris to its Board of Advisors. Harris brings decades of experience in leadership, athlete development and business management, and an unparalleled commitme...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch